MedTrace Logo

Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease

NCT06739486 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-12-18

No results posted yet for this study

Summary

evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease

Conditions

  • Non Alcholic Fatty Liver Disease
  • Hepatic Steatosis
  • Hepatic Fibrosis
  • NAFLD (Nonalcoholic Fatty Liver Disease)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Abdallah A Gamal, Resident · Assiut University

  • Lobna A Farag, Lecturer · Assiut University

  • Mohamed A Abozaid, Lecturer · Assiut University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2025-11-20
Completion
2025-12-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06739486 on ClinicalTrials.gov